106 related articles for article (PubMed ID: 38741503)
1. [Peripheral Neuropathy and Muscle Disorders as Immune-Related Adverse Events].
Suzuki S
Brain Nerve; 2024 May; 76(5):605-611. PubMed ID: 38741503
[TBL] [Abstract][Full Text] [Related]
2. Peripheral nervous system adverse events associated with immune checkpoint inhibitors.
Rossi S; Gelsomino F; Rinaldi R; Muccioli L; Comito F; Di Federico A; De Giglio A; Lamberti G; Andrini E; Mollica V; D'Angelo R; Baccari F; Zenesini C; Madia P; Raschi E; Cortelli P; Ardizzoni A; Guarino M
J Neurol; 2023 Jun; 270(6):2975-2986. PubMed ID: 36800019
[TBL] [Abstract][Full Text] [Related]
3. [Clinical Features of Myasthenia Gravis as an Immune-related Adverse Event].
Suzuki S
Brain Nerve; 2024 Jan; 76(1):27-32. PubMed ID: 38191136
[TBL] [Abstract][Full Text] [Related]
4. Neurological adverse events of immune checkpoint inhibitors: An update of clinical presentations, diagnosis, and management.
Farina A; Villagrán-García M; Honnorat J
Rev Neurol (Paris); 2023 Jun; 179(5):506-515. PubMed ID: 36934022
[TBL] [Abstract][Full Text] [Related]
5. Neurological disorders associated with immune checkpoint inhibitors: an association with autoantibodies.
Seki M; Kitano S; Suzuki S
Cancer Immunol Immunother; 2022 Apr; 71(4):769-775. PubMed ID: 34515815
[TBL] [Abstract][Full Text] [Related]
6. [Distinctive Disease Entity of Neurological Adverse Events Associated with Immune Checkpoint Inhibitors].
Seki M; Suzuki S
Brain Nerve; 2021 Jan; 73(1):35-46. PubMed ID: 33361512
[TBL] [Abstract][Full Text] [Related]
7. Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events.
Müller-Jensen L; Knauss S; Ginesta Roque L; Schinke C; Maierhof SK; Bartels F; Finke C; Rentzsch K; Ulrich C; Mohr R; Stenzel W; Endres M; Boehmerle W; Huehnchen P
Front Immunol; 2023; 14():1108116. PubMed ID: 36845122
[TBL] [Abstract][Full Text] [Related]
8. CNS and PNS manifestation in immune checkpoint inhibitors: A systematic review.
Khan E; Shrestha AK; Elkhooly M; Wilson H; Ebbert M; Srivastava S; Wen S; Rollins S; Sriwastava S
J Neurol Sci; 2022 Jan; 432():120089. PubMed ID: 34942546
[TBL] [Abstract][Full Text] [Related]
9. A systematic review of immune checkpoint inhibitor-related neurological adverse events and association with anti-neuronal autoantibodies.
Salim A; Tapia Rico G; Shaikh A; Brown MP
Expert Opin Biol Ther; 2021 Sep; 21(9):1237-1251. PubMed ID: 33645372
[No Abstract] [Full Text] [Related]
10. Do peripheral neuropathies differ among immune checkpoint inhibitors? Reports from the European post-marketing surveillance database in the past 10 years.
Ruggiero R; Balzano N; Di Napoli R; Fraenza F; Pentella C; Riccardi C; Donniacuo M; Tesorone M; Danesi R; Del Re M; Rossi F; Capuano A
Front Immunol; 2023; 14():1134436. PubMed ID: 37006303
[TBL] [Abstract][Full Text] [Related]
11. Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature.
Boutros A; Bottini A; Rossi G; Tanda ET; Spagnolo F; Barletta G; Croce E; Fava P; Parisi A; De Rosa F; Palla M; Marconcini R; Ferrari M; Grandis M; Spallarossa P; Sarocchi M; Arboscello E; Del Mastro L; Lambertini M; Pronzato P; Genova C
ESMO Open; 2023 Feb; 8(1):100791. PubMed ID: 36791639
[TBL] [Abstract][Full Text] [Related]
12. Severe neuromuscular immune-related adverse events of immune checkpoint inhibitors at national cancer center in Korea.
Hyun JW; Kim KH; Kim SH; Kim HJ
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5583-5589. PubMed ID: 36495331
[TBL] [Abstract][Full Text] [Related]
13. Exploring the role of immune checkpoint inhibitors in the etiology of myasthenia gravis and Lambert-Eaton myasthenic syndrome: A systematic review.
Seligman C; Chang YM; Luo J; Garden OA
Front Neurol; 2022; 13():1004810. PubMed ID: 36698907
[TBL] [Abstract][Full Text] [Related]
14. Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis.
Ngamphaiboon N; Ithimakin S; Siripoon T; Sintawichai N; Sriuranpong V
BMC Cancer; 2021 Nov; 21(1):1275. PubMed ID: 34823493
[TBL] [Abstract][Full Text] [Related]
15. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
[TBL] [Abstract][Full Text] [Related]
16. Dysautonomia associated with immune checkpoint inhibitors.
Tezuka T; Okuzumi S; Nakashima C; Ide T; Imai S; Mitsuboshi S; Kuwahara Y; Takizawa T; Seki M; Minematsu N; Aragane N; Nakahara J; Hori S; Nakane S; Suzuki S
J Neurol; 2023 Jul; 270(7):3413-3423. PubMed ID: 36939931
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature.
Reynolds KL; Guidon AC
Oncologist; 2019 Apr; 24(4):435-443. PubMed ID: 30482825
[TBL] [Abstract][Full Text] [Related]
18. Neurotoxicity and safety of the rechallenge of immune checkpoint inhibitors: a growing issue in neuro-oncology practice.
Villagrán-García M; Velasco R
Neurol Sci; 2022 Apr; 43(4):2339-2361. PubMed ID: 35175441
[TBL] [Abstract][Full Text] [Related]
19. Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications.
Cappelli LC; Bingham CO
Arthritis Rheumatol; 2021 Apr; 73(4):553-565. PubMed ID: 33186490
[TBL] [Abstract][Full Text] [Related]
20. Brief Communication: Lambert-Eaton Myasthenic Paraneoplastic Syndrome Associated With Merkel Cell Carcinoma Successfully Treated by Immune Checkpoint Inhibitors: 2 Cases.
Gra M; Pham-Ledard A; Gerard E; Dutriaux C; Beylot-Barry M; Duval F; Carla L; Soulages A; Prey S
J Immunother; 2023 Sep; 46(7):276-278. PubMed ID: 37326491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
